Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
出版年份 2014 全文链接
标题
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
作者
关键词
Cyclophosphamide, Metronomic administration, Ovarian cancer, Salvage treatment
出版物
BMC CANCER
Volume 14, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-12-14
DOI
10.1186/1471-2407-14-947
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Metronomics: towards personalized chemotherapy?
- (2014) Nicolas André et al. Nature Reviews Clinical Oncology
- Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
- (2013) Klas Norrby APMIS
- Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study
- (2013) Gabriella Ferrandina et al. GYNECOLOGIC ONCOLOGY
- Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- (2013) Marta Vives et al. INTERNATIONAL JOURNAL OF CANCER
- Advanced ovarian cancer: what should be the standard of care?
- (2013) Barbara A. Goff Journal of Gynecologic Oncology
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
- (2013) Lana E. Kandalaft et al. OncoImmunology
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors
- (2012) Romana Mikyšková et al. JOURNAL OF IMMUNOTHERAPY
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
- (2011) R. Wendel Naumann et al. DRUGS
- Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
- (2010) Yoh Watanabe et al. International Journal of Clinical Oncology
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
- (2009) Philipp Harter et al. Expert Review of Anticancer Therapy
- Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
- (2008) José Miguel Jurado García et al. Clinical & Translational Oncology
- Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
- (2008) Yoh Watanabe et al. International Journal of Clinical Oncology
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now